Phase III trial of dacarbazine versus dacarbazine with interferon α-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative oncology Group Study

Journal of Clinical Oncology

Volumn 16, Issue 5, 1998, Pages 1743-1751

  Falkson, Carla I ^a   Ibrahim, Joseph ^a   Kirkwood, John M ^a   Coates, Alan S ^a   Atkins, Michael B ^a   Blum, Ronald H ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; DACARBAZINE; TAMOXIFEN;

ADULT; AGED; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; WEIGHT REDUCTION;

EID: 0031805725     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.5.1743     Document Type: Article

References (41)

1. Costanza ME, Nathanson L, Schoenfeld D, et al: Results with methyl-CCNU and dacarbazine in metastatic melanoma. Cancer 40: 1010-1015, 1977
2. Hill GJ II, Krementz ET, Hill HZ: Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 53:1299-1305, 1984
3. Falkson G, van der Merwe AM, Falkson HC: Clinical experience with 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in the treatment of metastatic malignant melanoma. Cancer Chemother Rep 56:671-677, 1972
4. Carbone PP, Costello W: Eastern Cooperative Oncology Group studies with dacarbazine (NSC 45388). Cancer Treat Rep 60:193-198, 1976
5. Ramirez G, Wilson W, Grage T, et al: Phase II evaluation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU: NSC 409962) in patients with solid tumors. Cancer Chemother Rep 56:787-790, 1972
6. Del Prete SA, Maurer LH, O'Donnell J, et al: Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68:1403-1405, 1984
7. Ahmann DL: Nitrosoureas in the management of disseminated malignant melanoma. Cancer Treat Rep 60:747-751, 1976
8. Hoogstraten B, Gottlieb JA, Caoili E, et al: CCNU (1-(2-chloroethyl)-3 cyclohexyl-1-nitrosourea. NSC-79037) in the treatment of cancer. Cancer 32:38-43, 1973
9. Wasserman TH, Slavik M, Carter SK: Methyl-CCNU in clinical cancer therapy. Cancer Treat Rev 1:251-269, 1974
10. Young RC, Canellos GP, Chabner BA, et al: Treatment of malignant melanoma with methyl(CCNU). Clin Pharmacol Ther 15:617-622, 1974
11. Comis RL, Carter SK: Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. Cancer Treat Rev 1:285-304, 1974
12. Neefe JR, Legha SS, Markowitz A, et al: Phase II study of recombinant alfa-interferon in malignant melanoma. Am J Clin Oncol 13:472-476, 1990
13. Creagan ET, Schaid DJ, Ahmann DL, et al: Disseminated malignant melanoma and recombinant interferon: Analysis of seven consecutive phase II investigations. J Invest Dermatol 95:1885-1925, 1990
14. Kirkwood JM, Ernstoff MS: Role of interferons in the therapy of melanoma. J Invest Dermatol 95:1805-1845, 1990
15. Falkson CI, Falkson G, Falkson HC: Phase II trial of fotemustine in patients with metastatic malignant melanoma. Invest New Drugs 12:251-254, 1994
16. Mughal TI, Thomas MR, Roinson WA: Role of recombinant alfa-interferon in the treatment of advanced cutaneous malignant melanoma. Oncology 48:365-368, 1991
17. Kirkwood JM, Ernstoff MS, Davis CA, et al: Comparison of intramuscular and intravenous recombinant alfa-2 interferon in melanoma and other cancers. Ann Intern Med 103:32-36, 1985
18. Balch CM, Reinigen DS, Kirkwood JM, et al: Cutaneous melanoma, in de Vita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practices of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 1947-1994
19. Falkson CI, Falkson G, Falkson HC: Improved results with the addition of interferon afa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 9:1403-1408, 1991
20. Cocconi G, Bella M, Calabresi F, et al: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327:516-523, 1992
21. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
22. Kaplan EL, Meier P: Nonparametric estimations of incomplete observations. J Amer Stat Assoc 53:457-481, 1958
23. Cox DR: Regression models and life tables. J Royal Stat Soc B 34:187-202, 1972
24. Mulder NH, Willemse PHB, Schraffordt Koops H, et al: Dacarbazine (dacarbazine) and human recombinant interferon alfa-2a (Roferon) in the treatment of disseminated malignant melanoma. Br J Cancer 62:1006-1007, 1990
25. Coates AS, Segelov E: Long-term response to chemotherapy in patients with visceral metastatic melanoma. Ann Oncol 5:249-251, 1994
26. BREMIM Italian Cooperative Group: Phase II study of interferon alfa-2a and dacarbazine in advanced melanoma. Biological Response Modifiers in Melanoma. Eur J Cancer 28A: 1719-1720, 1992
27. Kirkwood JM, Ernstoff MS, Giuliano A, et al: Interferon alfa-2a and dacarbazine in melanoma. J Nat Cancer Inst 82:1062-1063, 1990
28. Thomson DB, Adena M, McLeon GRC, et al: Interferon-2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: Results of a multi-institutional Australian randomised trial. Melanoma Res 3:133-138, 1993
29. Kerr R, Pippen P, Mermel R, et al: Treatment of metastatic malignant melanoma with a combination of interferon alfa-2a (Roferon) and dacarbazine. Proc Am Soc Clin Oncol 8:288, 1989 (abstr)
30. Bajetta E, Negretti E, Giannotti B, et al. Phase II study of interferon alfa-2a and dacarbazine in advanced melanoma. Am J Clin Oncol 13:405-409, 1990
31. Bajetta E, Di Leo A, Zampino MG, et al: Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 12:806-811, 1994
32. Avril MF, Bonneterre J, Delaunay M, et al: Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma: Experience of the French Study Group. Cancer Chemother Pharmacol 27:81-84, 1990
33. Milani S, Mansutti M, Sandri P, et al: Phase II study with alfa-2b interferon and dacarbazine in advanced malignant melanoma. J Cancer Res Clin Oncol 116:222, 1990 (abstr)
34. Galvez CA, Bohamassa M: Advanced malignant melanoma: Dacarbazine plus RIFN-ALFA-2B versus dacarbazine alone. Eur J Cancer 27:155, 1991 (suppl 2; abstr)
35. Grohn P: Nimustine, dacarbazine and recombinant interferon alfa-2a in metastatic malignant melanoma. Acta Chir Scand 555:52-55, 1989
36. Hersey P, McLeon GR, Thomson DB: Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with dacarbazine: Long-term follow-up of two phase II studies. Br J Haematol 79:60-66, 1991
37. Breier S, Pensel R, Roffe C, et al: High-dose dacarbazine with recombinant human interferon alfa-2b (rhIFN2b) for the treatment of metastatic malignant melanoma (MMM). Proc Am Soc Clin Oncol 9:281, 1990 (abstr 1090)
38. Ferri W, Kirkwood JM, Vlock D, et al: Carboplatin plus dacarbazine plus ± tamoxifen for metastatic melanoma. Proc Am Soc Clin Oncol 12:396, 1993 (abstr 1358)
39. Rusthoven JJ, Quirt IC, Iscoe NA, et al: Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 14:2083-2090, 1996
40. Creagan ET, Ingle JN, Ahmann DL, et al: Phase II study of high-dose tamoxifen (NSC 180973) in patients with disseminated malignant melanoma. Cancer 49:1353-1354, 1982
41. Walpole ET, Thomson DB, Beadle GF, et al: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. Proc Clin Oncol Soc Aust 19:71, 1992 (abstr)